Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > ACADEMIA
ACADEMIA
- Sapporo Hospital Sorry for Ethical Guidelines Violations in Nesp Clinical Study
May 19, 2014
- Chiba University Hospital Suspends Use of Novartis’s Products in Response to Scandal over VART Study
May 12, 2014
- Careful Approach Needed in Legislating for Clinical Research: JAMS Pres.
May 8, 2014
- VART Lead Investigator “Wants to Seriously Take University Advice” on Retracting Diovan Papers
May 2, 2014
- Claims of Superior Cardiorenal Protective Effects of Diovan “Cannot Be Supported”: Outside Investigation of VART Study
April 30, 2014
- Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
- US Journal Corrects COI Disclosure to Clarify Involvement of Shionogi and Eli Lilly Japan in Paper on “Pain in Depression”
April 23, 2014
- JSBMR’s Guidelines Recommend Alendronate, Risedronate as First-Line Therapies for Steroid-Induced Osteoporosis Based on Available Data
April 22, 2014
- Public Hospitals Seeking to Avert Penalty Fee Cuts for Low Price Settlements
April 14, 2014
- JSH Publishes New Hypertension Guidelines
April 3, 2014
- Tolvaptan Reduces Body Weight, Improves Congestive Symptoms; Adverse Reactions Seen in Less than 20% of Patients: Interim Analysis of PMS Data
March 26, 2014
- Edoxaban Subgroup Analysis of East Asian Patients “Consistent” with Global Study Results: Researcher
March 25, 2014
- Revised Treatment Guidelines for HER2-Positive Gastric Cancer Will Recommend Combination Therapy with Trastuzumab
March 25, 2014
- Current Tax Rules for Medical Fees Unreasonable, Litigation an Option: Major Hospital Chain
March 25, 2014
- Experts Disagree over Full-Introduction of GCP at JCS Meeting
March 24, 2014
- NCNP Research Group Confirms Efficacy of Tocilizumab for Neuromyelitis Optica
March 19, 2014
- Japan Hematology Society to Open Probe into SIGN Trial
March 19, 2014
- Lead Author to Revise COI Statement in Article Used to Promote Antidepressant Cymbalta
March 19, 2014
- Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
- JSH Guidelines to Strongly Recommend Beta Blockers for Patients with Certain Complications
March 18, 2014
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…